invoX Belgium
0654.798.401 · rovalta.com · 25/09/2026
ACTIVE
invoX Belgium
Financial year 2025 · Closed on 31/12/2025
Net result-21 M €-29,5 %over 1 year
Gross margin2,2 M €-71,3 %over 1 year
Equity-64,6 M €-48,2 %over 1 year
Workforce45,5 ETP+66,1 %over 1 year
Overview
Identity
Source · BCE/KBOinvoX Belgium is a Public limited company incorporated in 2016. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Diepenbeek. It employs on average 45,5 ETP workers (FTE).
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0654.798.401
- Incorporation
- 27/04/2016
- Legal form
- Public limited company
- Registered office
- Agoralaan /
3590 Diepenbeek · FlandreSee on map - Contributed capital
- 22 770 366,23 €
- Latest accounts
- 31/12/2025
- Average workforce
- 45,5 ETP
Activities (NACE)
21201Manufacture of pharmaceutical preparations· main21201Manufacture of pharmaceutical preparations72109Research and experimental development on natural sciences and engineering72190Other research and experimental development on natural sciences and engineering74909Other professional, scientific and technical activities n.e.c.74999Other professional, scientific and technical activities n.e.c.
Signals
Healthy social debts
Financials
Source · NBB, 11 filingsTrend over 6 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 2,2 M € | -71.3% | 7,8 M € | +115% | 3,6 M € | +21.3% | 3 M € | +264% | -1,8 M € |
| EBITDA | -2,9 M € | -592% | -416,3 k € | +78.1% | -1,9 M € | -965% | -178,4 k € | +95.8% | -4,2 M € |
| Operating result | -18,3 M € | -43.8% | -12,7 M € | +15.0% | -14,9 M € | -111% | -7,1 M € | -67.9% | -4,2 M € |
| Net result | -21 M € | -29.5% | -16,2 M € | -3.8% | -15,6 M € | -110% | -7,4 M € | -55.3% | -4,8 M € |
| Balance sheet | |||||||||
| Equity | -64,6 M € | -48.2% | -43,6 M € | -59.3% | -27,3 M € | -133% | -11,7 M € | -174% | -4,3 M € |
| Total assets | 29,2 M € | +38.8% | 21,1 M € | +46.4% | 14,4 M € | +136% | 6,1 M € | +355% | 1,3 M € |
| Cash | 1,8 M € | +86.6% | 948,4 k € | -53.9% | 2,1 M € | +76.1% | 1,2 M € | -2.7% | 1,2 M € |
| Debts | 84,2 M € | +31.0% | 64,3 M € | +62.9% | 39,5 M € | +129% | 17,3 M € | +207% | 5,6 M € |
| Other | |||||||||
| Workforce | 45,5 ETP | +66.1% | 27,4 ETP | +31.1% | 20,9 ETP | +65.9% | 12,6 ETP | +75.0% | 7,2 ETP |
Board of directors
Source · NBB, accounts to 31/12/20251 active · 18 ended
Active mandates
invoX Pharma Limited
ActiveEnded mandates
Jan-Torsten Tews
EndedJurgen Rawert
EndedBenjamin Richard Toogood
EndedBenjamin Richard Toogood
EndedFinancials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 23/07/2026 | 18/07/2025 | 23/07/2024 | 19/07/2023 | 01/07/2022 | 01/07/2021 |
| General meeting | 30/06/2026 | 24/06/2025 | 30/06/2024 | 30/06/2023 | 21/06/2022 | 04/06/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 11 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 30/06/2026 | 23/07/2026 | Dutch | |
| Abridged model | 31/12/2024 | 24/06/2025 | 18/07/2025 | Dutch | |
| Abridged model | 31/12/2023 | 30/06/2024 | 23/07/2024 | Dutch | |
| Abridged model | 31/12/2022 | 30/06/2023 | 19/07/2023 | Dutch | |
| Abridged model | 31/12/2021 | 21/06/2022 | 01/07/2022 | Dutch | |
| Abridged model | 31/12/2020 | 04/06/2021 | 01/07/2021 | Dutch | |
| Abridged model | 31/12/2019 | 17/07/2020 | 27/07/2020 | Dutch | |
| Abridged model | 31/12/2018 | 27/06/2019 | 18/07/2019 | Dutch | |
| Abridged modelCorrection | 31/12/2017 | 29/06/2018 | 13/12/2018 | Dutch | |
| Abridged model | 31/12/2017 | 29/06/2018 | 09/07/2018 | Dutch | |
| Abridged model | 31/12/2016 | 16/06/2017 | 14/07/2017 | Dutch |
Valuation
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20251 active · 18 ended
Active mandates
invoX Pharma Limited
ActiveEnded mandates
Jan-Torsten Tews
EndedJurgen Rawert
EndedBenjamin Richard Toogood
EndedBenjamin Richard Toogood
EndedOwnership and network
Looking for more information about this company?
Try for freePublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Capital / shares03/08/2026STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN
- Mandates21/11/2025ONTSLAGEN - BENOEMINGEN
- Mandates01/09/2023STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - BENAMING - ONTSLAGEN - BENOEMINGEN
- Mandates14/07/2023ONTSLAGEN - BENOEMINGEN
- Mandates18/01/2023ONTSLAGEN - BENOEMINGEN
- Mandates09/08/2021ONTSLAGEN - BENOEMINGEN
- Mandates13/04/2021STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - ONTSLAGEN - BENOEMINGEN
- Capital / shares10/12/2020STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-21 M €↓
- 2024Annual accounts 2024-16,2 M €↓
- 2023Annual accounts 2023-15,6 M €↓
- 2023Name changeinvoX Belgium NV
- 2022Annual accounts 2022-7,4 M €↓
- 2021Annual accounts 2021-4,8 M €↓
- 2016Annual accounts 2016-343 k €
- 27/04/2016IncorporationPublic limited company
- 2016Name changeSofthale